Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats
Authors
Keywords
-
Journal
Scientific Reports
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-08-23
DOI
10.1038/s41598-017-09470-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
- (2017) Victoria K. Snowdon et al. PLOS MEDICINE
- Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes
- (2017) Hooi Hooi Ng et al. Scientific Reports
- Label-free fluorescence lifetime and second harmonic generation imaging microscopy improves quantification of experimental renal fibrosis
- (2016) Suman Ranjit et al. KIDNEY INTERNATIONAL
- Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis
- (2016) Vivette D. D'Agati et al. Nature Reviews Nephrology
- Exercise Training Attenuates Right Ventricular Remodeling in Rats with Pulmonary Arterial Stenosis
- (2016) Brunno Lemes de Melo et al. Frontiers in Physiology
- Regular exercise improves cardiac contractile activation by modulating MHC isoforms and SERCA activity in orchidectomized rats
- (2015) Pavarana Vutthasathien et al. JOURNAL OF APPLIED PHYSIOLOGY
- Imaging Fibrosis and Separating Collagens using Second Harmonic Generation and Phasor Approach to Fluorescence Lifetime Imaging
- (2015) Suman Ranjit et al. Scientific Reports
- Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions
- (2014) Javier Díez American Journal of Cardiovascular Drugs
- Serelaxin Is a More Efficacious Antifibrotic Than Enalapril in an Experimental Model of Heart Disease
- (2014) Chrishan S. Samuel et al. HYPERTENSION
- HMG-CoA Reductase Inhibitors in Chronic Kidney Disease
- (2013) A. Olyaei et al. American Journal of Cardiovascular Drugs
- A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure
- (2013) Piotr Ponikowski et al. EUROPEAN HEART JOURNAL
- Relaxin Family Peptides and Their Receptors
- (2013) R. A. D. Bathgate et al. PHYSIOLOGICAL REVIEWS
- Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
- (2012) John R Teerlink et al. LANCET
- Echocardiographic Parameters are Independently Associated with Rate of Renal Function Decline and Progression to Dialysis in Patients with Chronic Kidney Disease
- (2011) S.-C. Chen et al. Clinical Journal of the American Society of Nephrology
- The Role of Nitric Oxide on Endothelial Function
- (2011) Dimitris Tousoulis et al. Current Vascular Pharmacology
- Relaxin regulates vascular wall remodeling and passive mechanical properties in mice
- (2011) Dan O. Debrah et al. JOURNAL OF APPLIED PHYSIOLOGY
- Targeting Fibrosis for the Treatment of Heart Failure: A Role for Transforming Growth Factor-β
- (2010) Amanda J Edgley et al. Cardiovascular Therapeutics
- Relaxin in Human Pregnancy
- (2009) Laura T. Goldsmith et al. Annals of the New York Academy of Sciences
- Fluid overload in acute heart failure - Re-distribution and other mechanisms beyond fluid accumulation
- (2008) Gad Cotter et al. EUROPEAN JOURNAL OF HEART FAILURE
- Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2
- (2008) Ishanee Mookerjee et al. FASEB JOURNAL
- Relaxin, a pleiotropic vasodilator for the treatment of heart failure
- (2008) Sam L. Teichman et al. HEART FAILURE REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started